BJDX Bluejay DiagnosticsWatchlist
About Bluejay Diagnostics Company
Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally-invasive Point-of-Care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focus is on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Dey Indraneil on March 20, 2015 and is headquartered in Acton, MA.
Bluejay Diagnostics Q3 EPS $(2.08) Up From $(3.00) YoY
Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(2.08) per share. This is a 30.67 percent increase over losses of $(3.00) per share from the same period last year.
BlueJay Diagnostics Names Frances Scally As CFO, Replacing Kenneth R. Fisher
ACST, TRT and CNTX Among Mid-day Movers